TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Signed Informed Consent~* Able to swallow an oral medication~* Cardiac ejection fraction within the institutional range of normal as measured by echocardiogram~* Adequate kidney and liver function~* Adequate bone marrow function~* Tumor tissue available for testing~* Prior adjuvant or neoadjuvant therapy is permitted with an anthracycline or anthracenedione-containing regimen however, subjects must have had cumulative doses of less than 360 mg/m2 of doxorubicin, 720 mg/m2 of epirubicin, or 72 mg/m2 of mitoxantrone~* No Her2/neu overexpression in tumor tissue tested or status unknown if tissue has never been tested~Exclusion criteria:~* Prior treatment regimens for advanced or metastatic breast cancer.~* Pregnant or lactating~* Conditions that would effect the absorption of an oral drug~* Active infection~* Brain metastases~* Treatment with EGFR (Endothelial Growth Factor Receptor) inhibitor.~* Known hypersensitivity to Taxol or excipients of Taxol~* Peripheral neuropathy of Grade 2 or greater is not permitted~* Severe Cardiovascular disease or cardiac disease requiring a device.~* Serious medical or psychiatric disorder that would interfere with the patient's safety or informed consent.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Lapatinib 1500 mg, once daily and Paclitaxel 175 mg/m Intravenously over 3 hours ever 3 weeks
- Arm 2 (Type: PLACEBO_COMPARATOR): Paclitaxel 175 mg/m Intravenously over 3 hours ever 3 weeks and Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Risperidone in the Treatment of Psychotic-like and Deficit Symptoms of Schizotypal Personality Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Schizotypal Personality Disorder~Exclusion Criteria:~Over 65

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Risperidone (Type: EXPERIMENTAL): starting dose 0.25mg/day, titrated upward to 2mg/day over 9 weeks
- Placebo (Type: PLACEBO_COMPARATOR): placebo match in identical tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Eszopiclone in Patients With Generalized Anxiety Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
* Subjects, between the ages of 18 and 64 years inclusive~* Subjects with Generalized Anxiety Disorder (GAD)~* Subjects with insomnia related to GAD.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Escitalopram oxalate 10 mg at bedtime
- 2 (Type: ACTIVE_COMPARATOR): Eszopiclone 3 mg at bedtime

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of 17-Beta Estradiol in Treatment of Atrophic Vaginitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Generally healthy~* Postmenopausal~* Hysterectomized or non-hysterectomized~* Moderate or severe vaginal dryness and soreness~Exclusion Criteria:~* Known, suspected, or past history of breast cancer~* Known, suspected, or past history of hormone-dependent tumor~* Genital bleeding of unknown etiology~* Acute thrombophlebitis or thromboembolic disorders or a past history of these conditions, associated with previous estrogen use~* Vaginal infection~* Use of exogenous corticosteroids or sex hormones within 8 weeks of starting active treatment in study~* Use of vaginal, oral or vulvar homeopathic preparations within seven days of starting active treatment in study~* History of treatment with diethylstilbestrol

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness and Safety of Restylane Lyft With Lidocaine in the Dorsal Hand

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Subjects willing to comply with the requirements of the study and providing a signed written informed consent including release of copyright of hand images.~* Males or females, 22 years of age or older~* Willing and able to perform hand functionality tests .~Key Exclusion Criteria:~* History of allergy or hypersensitivity to injectable HA gel or to gram positive bacterial proteins.~* History of allergy or hypersensitivity to lidocaine or other amide type anesthetics.~* Previous hand surgery including sclerotherapy, or history of hand trauma.~* Advanced photo aged/ photo damaged skin or skin condition with very crinkled or fragile skin on the dorsal hands.

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Restylane Lyft with Lidocaine (Type: EXPERIMENTAL): None
- No Intervention (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Imaging Synaptic Density in Cocaine and Opiate Addiction In Vivo Using 11UCB-J PET

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 21-55 years;~* Voluntary, written, informed consent;~* Physically healthy by medical history, physical, neurological, ECG and laboratory examinations;~* DSM-5 criteria for Opiate Use Disorder;~* Documented evidence (by urine toxicology) of 2 weeks abstinence from cocaine and 4 weeks abstinence from opiates;~* For females, a negative serum pregnancy (HCG) test;~* Full scale and verbal IQs \> 80 (Wechsler Adult Intelligence Scale, Fourth Edition (WAIS-IV)).~Exclusion Criteria:~* A history of other substance dependence (e.g., alcohol, sedative hypnotics), except for nicotine;~* A primary DSM-5 Axis I major psychiatric disorder (e.g., schizophrenia, bipolar disorder, major depression, etc.) as determined by the Structured Clinical Interview for DSM-5 (SCID-5);~* A history of significant and uncontrolled medical (e.g., cardiovascular, diabetic/metabolic) or neurological (e.g., cerebrovascular, seizures, traumatic brain injury) illness;~* A history of seizures;~* Current use of psychotropic and/or potentially psychoactive prescription medications;~* Medical contraindications to participation in a magnetic resonance (MR) imaging procedure (e.g., ferromagnetic implants/foreign bodies, claustrophobia, cardiac pacemaker, prosthetic valve, otologic implant, etc.) as recorded on the MR safety sheet;~* For females, physical or laboratory (HCG) evidence of pregnancy;~* PTT and PT/INR lab results not appropriate for arterial line placement;~* Taking anticoagulants;~* Being prescribed methadone/buprenorphine upon screening.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Opiate Use Disorder (OUD) (Type: OTHER): 30 subjects meeting opiate dependence criteria will receive 11UCB-J PET Scan.
- Healthy Controls (HC) (Type: OTHER): 30 healthy controls; no substance dependence or mental health issues 11UCB-J PET Scan.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Post-market Clinical Follow-up of a Magnetic Bone Conduction Implant (Cochlear Baha Attract System)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Adult subject, i.e. ≥ 18 years of age~Conductive or mixed hearing loss in the ear to be implanted:~Bone conduction thresholds with a pure tone average PTA4 of \< 30 dB hearing level (mean of 500, 1000, 2000 and 4000 Hz).~OR~Single-sided sensorineural deafness (SSD):~European sites: Bone conduction thresholds with a pure tone average PTA4 of \< 30dB hearing level (mean of 500, 1000, 2000 and 4000 Hz) in the good ear.~US sites: Air conduction thresholds with a pure tone average PTA4 of 20 dB hearing level (mean of 500, 1000, 2000 and 3000 Hz) in the good ear OR Subject is indicated for an AC CROS but-for some reason-cannot or will not use an AC CROS.~No previous bone conduction implant on the side of the skull to be implanted. Signed informed consent.~Exclusion Criteria:~Subjects that are scheduled for simultaneous bilateral implant surgery. The investigation is limited to subjects with unilateral use of the Baha Attract System (however, bilateral hearing loss is not an exclusion criterion).~Suitable implant position for the BI300 Implant (4 mm or 3 mm) not found during surgery due to insufficient bone quality and/or bone thickness.~Less than 3 mm soft tissue thickness at the planned implant site. Subjects that have received radiation therapy at the same side of the skull where the Baha Attract System will be positioned.~Condition that could jeopardise osseointegration and/or wound healing as judged by the investigator (e.g. osteoporosis, psoriasis, use of corticosteroids).~Uncontrolled diabetes as judged by the investigator. Condition that may have an impact on the outcome of the investigation as judged by the investigator.~Unable to follow investigational procedures (e.g. to complete quality of life scales).~Participation in another investigation with pharmaceuticals and/or medical device.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Baha Attract System (Type: EXPERIMENTAL): This transcutaneous solution is based on a magnet coupling using magnets on both side of the skin;~* One implant magnet~* One external magnet on which a sound processor is attached, i.e. the Sound Processor magnet (SP magnet)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of histologically or cytologically confirmed NSCLC, stage IIIb with documented malignant pleural effusion or stage IV~* Immunohistochemical evidence of EGFR expression on tumor tissue~* Presence of at least 1 bi-dimensionally measurable index lesion, whereby index lesions must not lie in an irradiated area~Exclusion Criteria:~* Previous exposure to monoclonal antibodies, signal transduction inhibitors or EGFR-targeting therapy~* Previous chemotherapy for NSCLC~* Documented or symptomatic brain metastasis~* Superior vena cava syndrome contra-indicating hydration~* Previous malignancy in the last 5 years except basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cetuximab plus chemotherapy (Type: EXPERIMENTAL): cetuximab + cisplatin + vinorelbine
- Chemotherapy alone (Type: ACTIVE_COMPARATOR): cisplatin + vinorelbine alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of a Herbal Medicinal Product (Dry Extract BNO 1016) in Patients With Acute Rhinosinusitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Diagnosis of acute rhinosinusitis~* characterized by a major symptom score (MSS) ≥ 8 and ≤ 12 points (minimum 0, maximum 15 points)~* individual score for facial pain/pressure ≥ 1 (mild) and ≤ 2 (moderate)~* confirmed by ultrasonography of paranasal sinuses~* with presence of symptoms ≤ 3 days prior to inclusion~Exclusion Criteria:~* Chronic rhinosinusitis~* Polyposis nasi~* Anatomical deviations of the nasal septum that significantly impair nasal and paranasal ventilation/airflow~* Acute symptoms of a known allergic rhinitis~* Patients with asthma who have a history of exacerbations within 30 days prior to study inclusion~* Signs or symptoms of fulminant bacterial sinusitis~* Odontogenic sinusitis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- BNO 1016 (Type: EXPERIMENTAL): sugar coated tablets with dry extract (80 mg) of 5 herbal drugs; dosage: 480 mg per day (2 tablets t.i.d.) duration: 15 days
- Placebo (Type: PLACEBO_COMPARATOR): sugar coated tablets with identical appearance to active treatment; frequency: 2 tablets t.i.d. duration: 15 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Drug-drug Interaction Study(CKD-501, Amlodipine)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Between 20 aged and 45 years old in healthy males~* Body weight ≥ 55kg and 18.5 ≤ IBW \< 25~* Agreement with written informed consent~Exclusion Criteria:~* Subject has a history affects the ADME of drug~* Hypersensitivity reactions to drugs or clinically significant hypersensitivity reactions in the history of party~* Inadequate subject by medical examination(medical history, physical examination, ECG, laboratory test)~* AST,ALT \> UNL \* 1.25 or Total bilirubin \> UNL \* 1.5~* Estimated GFR(MDRD) \< 80~* SBP \>150 mmHg, SBP \< 100 mmHg or DBP \> 100 mmHg, DBP \< 60 mmHg or Pulse \> 100 per/min, Pulse \< 50 per/min~* Substance abuse, or a history of drug abuse showed a positive for the party~* Continued to be taking caffeine (caffeine \> 5 cup/day), drinking (alcohol \> 210 g/week) or cannot stop drinking or severe heavy smoker(cigarette \> 10 cigarettes per day)during clinical trials~* Medication with drug-mediated induction/inhibition metabolic enzyme within 30 days or with may affect the clinical trial~* Medication within 2 weeks in the first professional medical, medicine, OTC, vitamins taking~* Subject takes grapefruit within 1 month~* Previously participated in other trial within 60 days~* Previously donate whole blood within 60 days or component blood within 30 days~* An impossible one who participates in clinical trial by investigator's decision including laboratory test result

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- CKD-501 0.5mg (Type: EXPERIMENTAL): Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
- CKD-501 Amlodipine (Type: EXPERIMENTAL): Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
- Amlodipine 10mg (Type: EXPERIMENTAL): Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: OPTImal Management of Antithrombotic Agents: OPTIMA-2 Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion criteria:~1. Successively recruit all patients who receive stent implantation;~2. Intended use of standard DAPT with the combination of aspirin 100mg once daily and clopidogrel 75mg once daily for at least 12 months;~3. Patient aged \>18 years and ≦80 years old;~4. Signed inform consent.~Exclusion criteria:~1. Allergy or intolerance to study drugs;~2. History of gastrointestinal or intracranial bleeding;~3. Need for anticoagulant therapy;~4. High risk of bleeding (e.g., myelodysplasia, baseline platelet count \< 80 × 109/L);~5. Hemoglobin \< 90g/L;~6. Active malignancy or life expectancy \< 1 year;~7. Patients with other conditions made them unsuitable to be recruited at the discretion of the investigators.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CLOP-150 (Type: EXPERIMENTAL): clopidogrel 150mg once daily
- CLOP+CILOST (Type: EXPERIMENTAL): clopidogrel 75mg once daily plus cilostazol 100mg twice daily
- TICAG (Type: EXPERIMENTAL): ticagrelor 90mg twice daily
- CON(conventional DAPT) (Type: ACTIVE_COMPARATOR): clopidogrel 75mg once daily
- Non-HOPR (Type: ACTIVE_COMPARATOR): clopidogrel 75mg once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. 18 years of age or older (19 years of age or older in Canada)~2. Diagnosis of open angle glaucoma (OAG) or ocular hypertension(OHT) in both eyes~3. Unmedicated intraocular pressure \>20mmHg and \<36mmHg in both eyes at 2 qualification visits~4. Best corrected visual acuity (BCVA) equivalent to 20/200 Snellen or better~5. Able to give informed consent and follow study instructions~Exclusion Criteria:~Ophthalmic:~1. Clinically significant ocular disease~2. Pseudoexfoliation or pigment dispersion component glaucoma, history of angle closure or narrow angles~3. Unmedicated intraocular pressure ≥36mmHg in either eye or use of more than 2 ocular hypotensive medications within 30 days of screening~4. Known hypersensitivity to any component of the formulation or latanoprost~5. Previous glaucoma surgery or refractive surgery~6. Ocular trauma within 6 months prior to screening~7. Any ocular surgery or non-refractive laser treatment within 3 months prior to screening~8. Recent or current ocular infection or inflammation in either eye~9. Use of ocular medication in either eye of any kind within 30 days of screening and throughout of the study~10. Mean central corneal thickness \>620µm at screening in either eye~11. Any abnormality preventing reliable applanation tonometry of either eye~    Systemic:~12. Clinically significant abnormalities in lab tests at screening~13. Clinically significant systemic disease~14. Participation in any investigational study within 60 days prior to screening~15. Systemic medication that could have had a substantial effect on IOP within 30 days prior to screening, or anticipated to be used during the study~16. Women of childbearing potential who were pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- PG324 Ophthalmic Solution 0.02%/0.005% (Type: EXPERIMENTAL): Fixed combination of netarsudil 0.02%, latanoprost 0.005 % ophthalmic solution
- Netarsudil (AR-13324) ophthalmic solution 0.02% (Type: ACTIVE_COMPARATOR): Netarsudil 0.02% ophthalmic solution
- Latanoprost ophthalmic solution 0.005% (Type: ACTIVE_COMPARATOR): Latanoprost 0.005 % ophthalmic solution

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Monthly Darbepoetin Alfa Dosing for Correction of Anemia in Non-dialysis Chronic Kidney Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 years of age~* Diagnosis of chronic kidney disease with eGFR of 15-59 mL/min/1.73 m2 (MDRD equation)~* Two consecutive screening Hb values taken at least 7 days apart must each be \<10.0 g/dL~* TSAT ≥ 15%~Exclusion Criteria:~* Upper or lower GI bleeding within 6 months before enrolment~* ESA use within 12 weeks before enrolment~* Uncontrolled hypertension~* Systemic haematologic disorders~* Prior history within 12 weeks before enrollment of events including: Acute myocardial ischemia, unstable angina, myocardial infarction, hospitalization for congestive heart failure, stroke or transient ischaemic attack, limb ischaemia, deep vein thrombosis, thromboembolism.~* Grand mal seizure within 6 months prior to enrolment~* Evidence of, or received chemotherapy or radiation therapy for, a malignancy within 5 years prior to enrolment.~* Red blood cell transfusion within 12 weeks prior to enrolment~* Androgen therapy within 8 weeks prior to enrolment~* Pregnancy or breast feeding, or inadequate contraception~* Currently receiving immunosuppressive therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Q2W (Type: ACTIVE_COMPARATOR): Q2W administration of darbepoetin alfa.
- QM (Type: ACTIVE_COMPARATOR): QM administration of darbepoetin alfa

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete